Palvella Therapeutics, Inc. (PVLA) Free cash flow 2016–2023
Palvella Therapeutics, Inc. (PVLA) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$13.9MFY2023 · since FY2016: -$14.9M → -$13.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -$13.9M | +77.2% |
| FY2022 | -$61.0M | -608.2% |
| FY2021 | -$8.6M | +82.3% |
| FY2020 | -$48.6M | +11.5% |
| FY2019 | -$54.9M | -1887.3% |
| FY2018 | -$2.8M | -105.8% |
| FY2017 | $47.8M | +419.8% |
| FY2016 | -$14.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More PVLA financial trends
PVLA RevenuePVLA Net incomePVLA Net marginPVLA Gross profitPVLA Gross marginPVLA Operating incomePVLA Operating marginPVLA Operating cash flowPVLA Capital expendituresPVLA Return on equityPVLA Stock buybacksPVLA Dividends paidPVLA Total assetsPVLA Total liabilitiesPVLA Shareholders’ equityPVLA overview →